Latest Publications In The miRNA Field:

by Christoph on September 2, 2009

in Publications

Implication of Sperm RNA in Transgenerational Inheritance of the Effects of Early Trauma in Mice

Recent studies have suggested that early-life stressors and traumatic experiences can cause heritable changes in gene expression in future generations. Researchers at the University of Zurich’s Brain Research Institute hypothesized that early-life stressors in male mice may cause heritable changes in the small, non-coding RNA content (including miRNAs) in the sperm of traumatized mice and that this may induce behavioral changes in future progeny. Using RNA-Seq, global miRNA content in male sperm of controls and a model system of males subjected to unpredictable maternal separation combined with unpredictable maternal stress (MSUS) had significantly altered expression patterns. Additionally, miRNA in the sperm of MSUS mice exhibited altered miRNA expression in the serum and hippocampus. The changes in miRNA expression were similar in the serum and the hippocampus of F2 progeny of the MSUS males compared to control. However, the miRNA expression levels in F2 sperm were similar to normal controls. Despite this, F2 and F3 progeny exhibited [click to continue…]

{ 0 comments }

mrSNP workflowmrSNP is a highly adaptable and performing web based tool for predicting the effect a 3′UTR SNP will have on miRNA binding. This tool has advantages over existing algorithms because it can assess the effect of novel SNPs on miRNA binding without requiring significant hands on time.

Project home page: http://mrsnp.osu.edu
License: Free for commercial and academic use

Background

MicroRNAs (miRNAs) bind to sites in the 3′untranslated regions (3′UTR) of a targeted messenger RNA (mRNA). Binding leads to degradation of the transcript or blocked translation resulting in decreased expression of the targeted gene. Single nucleotide polymorphisms (SNPs) have been found in 3′UTRs that disrupt normal miRNA binding or introduce new binding sites and some of these have been associated with disease pathogenesis. This raises the importance of detecting miRNA targets and [click to continue…]

{ 0 comments }

Next-gen Sequencing and ncRNA, small RNA, miRNA data analysis workshopThe organizers are happy to announce the upcoming “NGS and non-coding RNA data analysis” workshop II (2014) 15-16 May, Plovdiv, Bulgaria

The SeqAhead COST action BM1006 is organizing a 2 day workshop with presentations on non-coding RNA (ncRNA) research, bioinformatics, data analysis and stimulating discussions between biologists and bioinformaticians. The registration for this COST WS is now open.

The Workshop will concentrate on current topics in NGS and non-coding RNAs, with special emphasis on data analysis. The ultimate goal of the workshop is to bring software developers, bioinformaticians and experimental scientists together, bridging the gap between users’ needs and developers’ goals.

Workshop Target:

-biologists with research in ncRNA (ncRNA, small RNAs, miRNAs) applying or planning to apply Next Generation Sequencing technologies
-bioinformaticians involved in data analysis or developing algorithms for data analysis of ncRNA data.

The workshop is open for everybody in the ncRNA and NGS field. The workshop is free of charge and participants have to pay their own hotel and travel. COST will offer travel reimbursement to some selected researchers and you will need to provide a poster abstract.
For more detailed information visit the WS homepage:

http://seqahead.plantgene.eu

For more specific information please contact Dr. Vesselin Baev {vebaev@plantgene.eu}

{ 1 comment }

Researchers at the University of Oxford and the Scripps Research Institute recently published an article evaluating the use of several different RT-qPCR normalization strategies when profiling miRNA gene expression in mouse serum. In their research article entitled “Assessment of RT-qPCR Normalization Strategies for Accurate Quantification of Extracellular microRNAs in Murine Serum,” Roberts et. al. compare three miRNA expression normalization strategies: 1.) normalization of miRNA expression to the average Cq (Ct) of all measured miRNA genes, 2.) Normalization of gene expression to individual miRNAs such as miR-16, miR-223, or miR-31 (all miRNA genes previously identified as normalization controls in the literature), and 3.) Normalization to a ‘spike-in’ external control miRNA gene expressed in C. elegans (cel-miR-39).

Normalization strategies have been an increasingly important topic in miRNA expression studies. This is especially true when profiling miRNA expression in serum or tissues and when quantifying miRNA genes which can have considerable variability in their endogenous expression. The authors identified a panel of 124 serum miRNA genes present in all their samples between normal, dystrophic, and dystrophic-treated mice. Their results suggest that [click to continue…]

{ 0 comments }

MicroRNA 491-3p & Pharmacogenetics: Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity

February 10, 2014

The goal of pharmacogenetics is to better understand human response to both environmental toxins and drug treatment. Recently, several laboratories have investigated the hypothesis that microRNA regulation of drug metabolizing enzymes may influence their expression and ultimately effect enzymatic activity and patient drug toxicities. Researchers at the Pennsylvania State Hershey College of Medicine and Washington […]

Read the full article →

starBase update: deciphering Pan-Cancer patterns of miRNAs, lncRNAs, ceRNAs and RNA-binding proteins from TCGA 14 cancer types

February 8, 2014

StarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations). StarBase provides the following Pan-Cancer Analysis Services: […]

Read the full article →

DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

January 2, 2014

MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a […]

Read the full article →

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics

January 2, 2014

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34 BOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their […]

Read the full article →

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer

November 7, 2013

Expands the Company’s Patent Portfolio in Oncology Therapeutics PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting […]

Read the full article →

microRNA-122: Positive Preclinical Profile of a GalNAc-conjugated anti-miR Supports Clinical Development for the Treatment of HCV

November 4, 2013

Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of […]

Read the full article →